IL90973A - Medicinal preparations containing a history of benzapine for the treatment of neurological diseases - Google Patents
Medicinal preparations containing a history of benzapine for the treatment of neurological diseasesInfo
- Publication number
- IL90973A IL90973A IL9097389A IL9097389A IL90973A IL 90973 A IL90973 A IL 90973A IL 9097389 A IL9097389 A IL 9097389A IL 9097389 A IL9097389 A IL 9097389A IL 90973 A IL90973 A IL 90973A
- Authority
- IL
- Israel
- Prior art keywords
- hydroxy
- hydrogen
- hexahydro
- azepine
- alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 150000008038 benzoazepines Chemical class 0.000 title abstract description 3
- 208000012902 Nervous system disease Diseases 0.000 title description 2
- 208000025966 Neurological disease Diseases 0.000 title description 2
- 208000016285 Movement disease Diseases 0.000 claims abstract description 13
- 206010013663 drug dependence Diseases 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 230000004006 stereotypic behavior Effects 0.000 claims abstract description 12
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 47
- 239000001257 hydrogen Substances 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- -1 1-azetidinyl Chemical group 0.000 claims description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 206010008748 Chorea Diseases 0.000 claims description 3
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 3
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 208000012601 choreatic disease Diseases 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 229930192474 thiophene Natural products 0.000 claims description 3
- OMFJIBWDOQMUCP-UHFFFAOYSA-N 2-methoxy-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-3-ol Chemical compound CN1CCC2=CC=CC=C2C2C(C=C(C(=C3)O)OC)=C3CCC21 OMFJIBWDOQMUCP-UHFFFAOYSA-N 0.000 claims description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 201000006145 cocaine dependence Diseases 0.000 claims description 2
- CYONELLVDDZHTG-UHFFFAOYSA-N l002356 Chemical compound C1CN(C)C2CC3=CC=CC=C3C2C2=C1C=C(OC)C(O)=C2 CYONELLVDDZHTG-UHFFFAOYSA-N 0.000 claims description 2
- BQIFFQMONGGUNK-UHFFFAOYSA-N l002357 Chemical compound CN1CCC2=CC(Cl)=C(N)C=C2C2C3=CC=CC=C3CC12 BQIFFQMONGGUNK-UHFFFAOYSA-N 0.000 claims description 2
- YDJRHFYFVMQOGN-UHFFFAOYSA-N l002360 Chemical compound C1CC=2C=C(Cl)C(O)=CC=2C(C2=CC=CC=C2C2)C2N1CC1CC1 YDJRHFYFVMQOGN-UHFFFAOYSA-N 0.000 claims description 2
- MABLKMYKDXQGNI-UHFFFAOYSA-N l002362 Chemical compound CN1CCC2=CC(Cl)=C(O)C=C2C2C3=CC=CC=C3C(C)(C)C12 MABLKMYKDXQGNI-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 208000008013 morphine dependence Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 16
- 125000005605 benzo group Chemical group 0.000 claims 2
- YGLDQFWPUCURIP-UHFFFAOYSA-N 3h-3-benzazepine Chemical compound C1=CNC=CC2=CC=CC=C21 YGLDQFWPUCURIP-UHFFFAOYSA-N 0.000 claims 1
- XLQPWCBOBYYMJM-UHFFFAOYSA-N 5-chloro-10-azatetracyclo[9.7.0.02,7.013,18]octadeca-2,4,6,13,15,17-hexaen-4-ol Chemical compound C1C2=CC=CC=C2C2C1NCCC1=C2C=C(O)C(Cl)=C1 XLQPWCBOBYYMJM-UHFFFAOYSA-N 0.000 claims 1
- VNEAXGDDZAEBKG-UHFFFAOYSA-N chromeno[4,3-a][3]benzazepin-12-ol Chemical compound C1=CC=CC2=C1C=1C(N=CC=C3C=1C=C(C=C3)O)=CO2 VNEAXGDDZAEBKG-UHFFFAOYSA-N 0.000 claims 1
- GPEVLKQUROXSNS-UHFFFAOYSA-N l002353 Chemical compound CN1CCC2=CC(Cl)=C(O)C=C2C2C3=CC=CC=C3CC12 GPEVLKQUROXSNS-UHFFFAOYSA-N 0.000 claims 1
- ZMFZMAPTEWAFCZ-UHFFFAOYSA-N l002358 Chemical compound CN1CCC2=CC=C(O)C=C2C2C3=CC=CC=C3CC12 ZMFZMAPTEWAFCZ-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- FBABDBSOFPUQMW-UHFFFAOYSA-N 5h-benzo[g][1]benzazepine Chemical compound N1C=CC=CC2=C1C=CC1=CC=CC=C21 FBABDBSOFPUQMW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- WHADGAAMWFCDGX-UHFFFAOYSA-N 12-methoxy-7-methyl-6a,8,9,13b-tetrahydro-6h-chromeno[4,3-a][3]benzazepine Chemical compound C1CN(C)C2COC3=CC=CC=C3C2C2=CC(OC)=CC=C21 WHADGAAMWFCDGX-UHFFFAOYSA-N 0.000 description 1
- TUCYWBVWKLKPMG-UHFFFAOYSA-N 1h-1-benzazepin-2-ol Chemical compound N1C(O)=CC=CC2=CC=CC=C21 TUCYWBVWKLKPMG-UHFFFAOYSA-N 0.000 description 1
- MWVMYAWMFTVYED-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC=CC=C21 MWVMYAWMFTVYED-UHFFFAOYSA-N 0.000 description 1
- YEUFVOFLAMBYQF-UHFFFAOYSA-N 4-methoxy-10-methyl-10-azatetracyclo[9.9.0.02,7.015,20]icosa-2,4,6,15,17,19-hexaen-5-ol Chemical compound C1CCC2=CC=CC=C2C2C(C=C(C(=C3)O)OC)=C3CCN(C)C12 YEUFVOFLAMBYQF-UHFFFAOYSA-N 0.000 description 1
- YFUATDDQCBXIMG-UHFFFAOYSA-N 5-methoxy-10-methyl-10-azatetracyclo[9.9.0.02,7.015,20]icosa-2,4,6,15,17,19-hexaen-4-ol Chemical compound C1CN(C)C2CCCC3=CC=CC=C3C2C2=C1C=C(OC)C(O)=C2 YFUATDDQCBXIMG-UHFFFAOYSA-N 0.000 description 1
- BUVSNJJHJCALAD-UHFFFAOYSA-N 7-methyl-6a,8,9,13b-tetrahydro-6h-chromeno[4,3-a][3]benzazepin-12-ol Chemical compound CN1CCC2=CC=C(O)C=C2C2C3=CC=CC=C3OCC12 BUVSNJJHJCALAD-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002959 anti-hypotensive effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- OCRCAVKXNOGOEK-UHFFFAOYSA-N l002359 Chemical compound CN1CCC2=CC(C)=C(O)C=C2C2C3=CC=CC=C3CC12 OCRCAVKXNOGOEK-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/223,739 US4973586A (en) | 1986-01-16 | 1988-07-18 | Fused benzazepines, compositions of, and medical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL90973A true IL90973A (en) | 1994-04-12 |
Family
ID=22837795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9097389A IL90973A (en) | 1988-07-18 | 1989-07-14 | Medicinal preparations containing a history of benzapine for the treatment of neurological diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4973586A (de) |
| EP (2) | EP0351733B1 (de) |
| JP (1) | JPH0662420B2 (de) |
| KR (1) | KR900701275A (de) |
| AT (1) | ATE131056T1 (de) |
| AU (1) | AU634973B2 (de) |
| CA (1) | CA1336823C (de) |
| DE (1) | DE68925004T2 (de) |
| DK (1) | DK302190A (de) |
| ES (1) | ES2080736T3 (de) |
| IL (1) | IL90973A (de) |
| WO (1) | WO1990000853A2 (de) |
| ZA (1) | ZA895343B (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5302716A (en) * | 1986-01-16 | 1994-04-12 | Schering Corporation | Fused benzazepines |
| US5091526A (en) * | 1988-07-29 | 1992-02-25 | Schering Corporation | Process for the enantiospecific synthesis of intermediates for hexahydro-benzo[d]-naphtho[2,1-b]azepines |
| CA2016465A1 (en) * | 1989-06-02 | 1990-12-02 | Zola Phillip Horovitz | Method for preventing or treating anxiety employing a calcium channel blocker |
| EP0513174B1 (de) * | 1990-02-02 | 1995-08-16 | Schering Corporation | 4,5-cycloalkano-3-benzazepin-7-ol-derivate und ihre verwendung |
| US5312819A (en) * | 1990-08-20 | 1994-05-17 | Sandoz Ltd. | Pharmaceutical compositions comprising clozapine and a radical scavenger |
| US5463051A (en) * | 1993-09-27 | 1995-10-31 | Schering Corporation | Process for preparing benzazepine intermediates for the synthesis of D1 antagonists |
| US5461147A (en) * | 1993-09-27 | 1995-10-24 | Schering Corporation | Process for preparing benzazepine intermediates for the synthesis of D1 antagonists |
| US5461148A (en) * | 1993-09-27 | 1995-10-24 | Schering Corporation | Process for preparing benzazepine intermediates for the synthesis of D1 antagonists |
| CA2304592A1 (en) * | 1997-09-24 | 1999-04-01 | The General Hospital Corporation | Inhibition of psychostimulant-induced and nicotine-induced craving |
| US6410527B1 (en) | 1998-03-02 | 2002-06-25 | Schering Corporation | Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism |
| US6875866B2 (en) * | 2002-02-21 | 2005-04-05 | Schering Corporation | Process for synthesis of D1 receptor antagonists |
| DE60321354D1 (de) * | 2002-08-29 | 2008-07-10 | Schering Corp | Selektive d1/d5 rezeptorantagonisten zur behandlung von fettleibigkeit und von zns störungen |
| WO2005035504A2 (en) * | 2003-05-22 | 2005-04-21 | Schering Corporation | 5-h -benzo [d] naphth [2, 1-b] azepine derivative as selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders |
| PL3919060T3 (pl) | 2012-07-12 | 2025-10-20 | Emalex Biosciences, Inc. | Ekopipam do leczenia zespołu tourette'a |
| SI3057595T1 (sl) | 2013-10-18 | 2020-09-30 | Emalex Biosciences, Inc. | Spojeni benzazepini za zdravljenje jecljanja |
| WO2025194153A1 (en) | 2024-03-15 | 2025-09-18 | Emalex Biosciences, Inc. | Pharmaceutical dosage forms and methods of use |
| US12594281B2 (en) | 2024-03-15 | 2026-04-07 | Emalex Biosciences, Inc. | Pharmaceutical dosage forms and methods of use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3393192A (en) * | 1965-04-26 | 1968-07-16 | Schering Corp | Novel benzazepines |
| GB1118688A (en) * | 1967-02-17 | 1968-07-03 | Scherico Ltd | Novel benzazepines and process for making same |
| CH481110A (de) * | 1967-02-17 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen |
| US3609138A (en) * | 1967-12-22 | 1971-09-28 | Ciba Geigy Corp | 1-aryl-3-benzazepines |
| NL7206204A (de) * | 1971-05-10 | 1972-11-14 | ||
| US3983234A (en) * | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
| US3939165A (en) * | 1974-11-14 | 1976-02-17 | Morton-Norwich Products, Inc. | 5,6,6A,6B,7,8-Hexahydrobenz[a]phenanthridine hydrochloride |
| US4011319A (en) * | 1975-07-02 | 1977-03-08 | Smithkline Corporation | Pharmaceutical compositions and methods involving benzazepine derivatives |
| US4284555A (en) * | 1979-04-27 | 1981-08-18 | Schering Corporation | 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines |
| US4315926A (en) * | 1979-12-26 | 1982-02-16 | Ciba-Geigy Corporation | Dibenz[c,e]azepines |
| US4477378A (en) * | 1980-02-05 | 1984-10-16 | Schering Corp. | Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines |
| DE3007710C2 (de) * | 1980-02-29 | 1982-04-15 | Gödecke AG, 1000 Berlin | 5,6;8,9-Tetrahydro-7H-dibenz(d,f)azonin-derivate, Verfahren zu deren Herstellung und Arzneimittel |
| AU588080B2 (en) * | 1986-01-16 | 1989-09-07 | Schering Corporation | Fused benzazepines |
| JPH0678317B2 (ja) | 1987-07-15 | 1994-10-05 | シェリング・コーポレーション | 縮合ベンズアゼピン |
-
1988
- 1988-07-18 US US07/223,739 patent/US4973586A/en not_active Expired - Lifetime
-
1989
- 1989-07-13 ZA ZA895343A patent/ZA895343B/xx unknown
- 1989-07-14 JP JP1508220A patent/JPH0662420B2/ja not_active Expired - Fee Related
- 1989-07-14 DE DE68925004T patent/DE68925004T2/de not_active Expired - Fee Related
- 1989-07-14 CA CA000605690A patent/CA1336823C/en not_active Expired - Fee Related
- 1989-07-14 ES ES89112959T patent/ES2080736T3/es not_active Expired - Lifetime
- 1989-07-14 AU AU39884/89A patent/AU634973B2/en not_active Ceased
- 1989-07-14 EP EP89112959A patent/EP0351733B1/de not_active Expired - Lifetime
- 1989-07-14 WO PCT/US1989/002997 patent/WO1990000853A2/en not_active Ceased
- 1989-07-14 EP EP89908786A patent/EP0434695A1/de active Pending
- 1989-07-14 AT AT89112959T patent/ATE131056T1/de not_active IP Right Cessation
- 1989-07-14 IL IL9097389A patent/IL90973A/en not_active IP Right Cessation
-
1990
- 1990-03-16 KR KR1019900700564A patent/KR900701275A/ko not_active Ceased
- 1990-12-20 DK DK302190A patent/DK302190A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA895343B (en) | 1991-03-27 |
| AU3988489A (en) | 1990-02-19 |
| KR900701275A (ko) | 1990-12-01 |
| ES2080736T3 (es) | 1996-02-16 |
| DK302190A (da) | 1991-01-11 |
| JPH03502100A (ja) | 1991-05-16 |
| JPH0662420B2 (ja) | 1994-08-17 |
| US4973586A (en) | 1990-11-27 |
| WO1990000853A2 (en) | 1990-02-08 |
| EP0434695A1 (de) | 1991-07-03 |
| DE68925004D1 (de) | 1996-01-18 |
| DE68925004T2 (de) | 1996-05-15 |
| EP0351733A1 (de) | 1990-01-24 |
| AU634973B2 (en) | 1993-03-11 |
| EP0351733B1 (de) | 1995-12-06 |
| DK302190D0 (da) | 1990-12-20 |
| CA1336823C (en) | 1995-08-29 |
| WO1990000853A8 (en) | 2005-06-16 |
| ATE131056T1 (de) | 1995-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1336823C (en) | Method of treating neurological disorders | |
| AU593051B2 (en) | Method of treating alzheimer's disease | |
| AU630251B2 (en) | Dipyridodiazepines | |
| EP0216555B1 (de) | Verwendung von Dioxopiperidin-Derivaten zur Behandlung von Anxietas, zur Herabsetzung von chronischen abnormal hohen Gehirn-Spiegeln Serotonins oder 5-Hydroxy-Indolessigsäure und zur Behandlung von bakteriellen oder viralen Infektionen | |
| SI9400091A (en) | Substituted pyrrolo(2,3-b)pyridine derivatives | |
| HUP0301346A2 (hu) | Szterotonin agonista (5HT2) és antagonista (5HT6) új kombinációja gyógyászati készítményként és eljárás az előállítására | |
| IL96486A0 (en) | Tricyclic compounds,their preparation and pharmaceutical compositions containing them | |
| PL190218B1 (pl) | Pochodna 5H-tiazolo[3,2-a]pirymidyny, sposób jej wytwarzania i zawierający ją lek oraz jej zastosowanie | |
| EP0229444B1 (de) | Arzneimittel zur Behandlung von Anxietas | |
| HU185089B (en) | Process for producing imidazo-diazepine derivatives | |
| PT85975B (pt) | Processo para a preparacao de 6,11-di-hidro-11-(4-piperidilideno)-5h-benzo{5,6}ciclo-hepta{1,2-b}piridinas e de composicoes farmaceuticas que as contem | |
| CA2490254A1 (en) | Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | |
| JPH04501267A (ja) | 骨髄造血の刺激に有用なヘテロアリール―３―オキソ―プロパンニトリル誘導体 | |
| EP0400665A2 (de) | Verwendung von Calcium-Kanal-Blockern zur Prävention und Behandlung von Angstzuständen | |
| EP0393696A2 (de) | 7-(Substituierte)amino)-8-(substituierte)Carbonyl)methylamino-1-oxaspiro(4,5)decaben als harntreibende, entzündungshemmende und zerebrovaskuläre Mittel | |
| JPH10502657A (ja) | ヘテロ環縮合モルヒノイド誘導体 | |
| KR19990067528A (ko) | 카인산 신경 세포 독성 억제제 및 피리도티아진 유도체 | |
| CZ290678B6 (cs) | 3-Substituované 3,4,5,7-tetrahydropyrrolo[3´,4´: 4,5]thieno[2,3-d]pyrimidinové deriváty, způsob jejich přípravy a použití | |
| US3840523A (en) | Tricyclic arylalkylene lactamimides | |
| EP0394471A1 (de) | Thienocycloheptapyridazin-verbindungen und verwendung als arzneimittel | |
| WO2004033460A1 (en) | 5-cycloalkenyl 5h-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | |
| RU98115386A (ru) | Производные пиридо-1,2,4-тиадиазина и пиридо-1,4-тиазина, их получение и использование | |
| US3749785A (en) | Pharmaceutical compositions containing a tricyclic heterocyclic amide of a diallylamino-alkanoic acid | |
| HU201759B (en) | Process for producing new condensed diazepinones and pharmaceutical compositions comprising same | |
| CA1267894A (en) | 4-substituted 10-cyanomethylenethieno[4,3-e] benzoazepines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void |